In vitro inhibitory effects of Kampo medicines on metabolic reactions catalyzed by human liver microsomes

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 4, 2003, Pages 319-327

  Takahashi, K ^a,c   Uejima, E ^b   Morisaki, T ^a   Kurokawa, N ^b   Azuma, Junichi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

CYP450 activity; Drug interaction; Human liver microsomes; Kampo medicine

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; AMLODIPINE; ANXIOLYTIC AGENT; ASTEMIZOLE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CISAPRIDE; CLARITHROMYCIN; CLOMIPRAMINE; CYCLOSPORIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIAZEPAM; DICLOFENAC; ERGOTAMINE TARTRATE; ETHINYLESTRADIOL; IMIPRAMINE; KAMPO; MESTRANOL; PHENYTOIN; PREDNISOLONE; SIMVASTATIN; TAMOXIFEN; TERFENADINE; THEOPHYLLINE; UNINDEXED DRUG;

ARTICLE; CATALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER METABOLISM; LIVER MICROSOME;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUGS, CHINESE HERBAL; HERB-DRUG INTERACTIONS; HUMANS; ISOENZYMES; MEDICINE, KAMPO; MICROSOMES, LIVER;

EID: 0041378080     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00500.x     Document Type: Article

References (23)

1. Terasawa K (1993) KAMPO: Japanese-oriental medicine insights from clinical cases. Tokyo: K.K. Standard Mcintyre.
2. Bourrie M, Munier V, Berger Y, Fabre G (1996) Cytochrome P450 isoform inhibition as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321-332.
3. Ito K, Iwatsubo K, Kanajitsu S, Ueda K, Suzuki H, Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacological Reviews, 50, 387-411.
4. Guengerich FP (1995) Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450: structure, mechanism, and biochemistry. New York: Plenum, 473-536.
5. Pelkonen O, Maenpaa J, Taavitsainen P, Raunio H (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica, 28, 1203-1253.
6. Ioannides C. (1996) Cytochrome P450: metabolic and toxicological aspects. New York: CRC Press.
7. Tateishi T, Nakura H, Asoh M et al. (1997) A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sciences, 61, 2567-2574.
8. Akase T, Tashiro S, Ishibashi A et al. (2001) Pharmacoepidemiological study of the clinical efficacy of Sho-saiko-to (Xiao-Chai-Hu-Tang) in chronic liver desease patients. Journal of Traditional Medicine, 18, 95-106.
9. Bailey DG, Malcoim J, Arnold O, Spence JD (1998) Grapefruit juice-drug interactions. British Journal of Clinical Pharmacology, 46, 101-110.
10. Guo LQ, Taniguchi M, Chen QY, Baba K, Yamazoe Y (2001) Inhibitory potential of herbal medicines on human cytochrome P450-mediated oxidation: properties of Umbelliferous or Citrus crude drugs and their relative prescriptions. Japanese Journal of Pharmacology, 85, 399-408.
11. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB (1992) Identification of refampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. Journal of Clinical Investigation, 90, 1871-1878.
12. Boxenbaum H (1999) Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. Journal of Pharmacy & Pharmaceutical Sciences, 2, 47-52.
13. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology, 39, 1-17.
14. Hesse LM, Venkatakrishnan K, von Moltke LL, Shader RI, Greenblatt DJ (2001) CYP3A4 is the major CYP isoform mediating the in vitro hydroxidation and demethylation of flunitrazepam. Drug Metabolism and Disposition, 29, 133-140.
15. Wang RW, Newton DJ, Scheri TD, Lu AY (1997) Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metabolism and Disposition, 25, 502-507.
16. Wacher VJ, Silverman JA, Zhang Y, Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides an dpeptidomimetics. Journal of Pharmaceutical Science, 87, 1322-1330.
17. Homma M, Oka K, Ikeshima K, Takahashi N, Niitsuma T, Fukuda T, Itoh H (1995) Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. Journal of Pharmacy and Pharmacology, 47, 687-692.
18. Hasegawa T, Yamaki K, Nadai M, Muraoka I, Wang L, Takagi K, Nabeshima T (1994) Lack of effect of Chinese medicines on bioavailability of ofloxacin in healthy volunteers. International Journal of Clinical Pharmacology and therapeutics, 32, 57-61.
19. Ernst E (1998) Harmless herb? A review of the recent literature. American Journal of Medicine, 104, 170-178.
20. Eisenberg D, David RB, Ettner SL, Appel S, Wilkey S, van Rompay M, Kessler RC (1998) Trends in alternative medicine use in the United States, 1990-1997. JAMA, 280, 1569-1575.
21. Ernst E (2000) Herb-drug interactions: potentially important but woefully under-researched. European Journal of Clinical Pharmacology, 56, 523-524.
22. Fugh-Berman A (2000) Herb-drug interactions. Lancet, 355, 134-138.
23. Fugh-Berman A, Ernst E (2001) Herb-drug interactions: review and assessment of report reliability. British Journal of Clinical Pharmacology, 52, 587-595.